{'fraction_non_alphanumeric': 0.03208556149732621, 'fraction_numerical': 0.015448603683897801, 'mean_word_length': 5.378787878787879, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of the leukotriene B4 receptor, LTB4R, is perturbed in the blood of patients with Crohn’s Disease.

first-line treatment which includes the 5-aminosalicylate drug mesalamine and steroids (2, 3). Both of these drugs are thought to have physiologically pleiotropic functions but it is still not understood how these drugs exert their therapeutic function in CD (4,5). Deciphering their mechanism of action can be facilitated by a basic understanding of the relevant therapeutic targets in patients with Crohn’s Disease, and can assist in determining which patients will benefit from first-line treatment with mesalamine versus top-down treatment with biologics (6) which are more beneficial but also more costly and associated with an increased risk of development of non-Hodgkin’s and hepatosplenic T-cell lymphomas (7, 8, 9). Transcriptome analysis to understand how gene expression differs in the tissues of patients with Crohn’s Disease can facilitate this understanding. We found, using two published datasets (10, 11), that the leukotriene B4 receptor, LTB4R (12, 13), was among the genes whose expression was most different when comparing blood from patients with Crohn’s Disease with blood from healthy, non-affected subjects. Interestingly, while LTB4R was also a differentially expressed gene in CD4+ CD25+ regulatory T-cells from patients with Crohn’s Disease, in Treg it was expressed at significantly lower levels compared to non-affected subjects as opposed to whole blood where it was expressed at significantly higher levels. This is the first report documenting differential expression of LTB4R in the hematopoietic tissues of patients with Crohn’s Disease.